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ABSTRACT: On the basis of N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-
methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (II, ASS234) and
QSAR predictions, in this work we have designed, synthesized, and evaluated
a number of new indole derivatives from which we have identiﬁed N-methyl-
N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-
yl)methyl)prop-2-yn-1-amine (2, MBA236) as a new cholinesterase and
monoamine oxidase dual inhibitor.
■ INTRODUCTION
Alzheimer’s disease (AD) is an age-related neurodegenerative
disorder that accounts for approximatively 70% of adult
dementia.1 Worldwide, it is estimated that 40 million people
suﬀer from AD, and the prevalence of AD is expected to rise
signiﬁcantly in the next decades, as the average age of the
population increases.2 AD is characterized by a progressive
memory loss and a decline in language skills and other
cognitive impairments.3 Although the etiology of AD is not
completely known, common hallmarks, such as amyloid-β
(Aβ)4 deposits, τ-protein aggregation,5 and oxidative stress,6 are
thought to play key roles in the pathophysiology of the disease.7
In addition, the selective loss of cholinergic neurons in AD
results in a deﬁcit of acetylcholine (ACh) in speciﬁc brain
regions that mediate learning and memory.8 However,
alterations in other neurotransmitter systems, specially
serotoninergic and dopaminergic, are also thought to be
responsible for the behavioral disturbances observed in AD
patients.9
Monoamine oxidase (MAO; EC1.4.3.4), the enzyme that
catalyzes the oxidative deamination of a variety of biogenic and
xenobiotic amines,10 is also an important target to be
considered for the treatment of speciﬁc features of AD. MAO
exists as two distinct enzymatic isoforms, MAO-A and MAO-B,
based on their substrate and inhibitor speciﬁcities.11 MAO-A
preferentially deaminates serotonin, adrenaline, and noradrena-
line and is selectively and irreversibly inhibited by clorgyline. In
contrast, MAO-B preferentially deaminates β-phenylethylamine
and benzylamine and is irreversibly inhibited by L-deprenyl.12
Selective inhibitors for MAO-A are eﬀective antidepressants,
whereas MAO-B inhibitors are useful in the treatment of
Parkinson’s disease (PD)13 and might also be valuable for the
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treatment of AD.14 In fact, MAO-B inhibitors are also currently
in clinical trials for the treatment of AD because an increased
level of MAO-B has been detected in the plaque-associated
astrocytes of brains from AD patients.15
At present, there are three FDA-approved drugs (donepezil,
galantamine, and rivastigmine)16,17 that improve AD symptoms
by inhibiting acetylcholinesterase (AChE; EC1.1.1.7), i.e., the
enzyme responsible for the hydrolysis of ACh, and thereby
raising ACh content in the synapsis. Apart from the beneﬁcial
palliative properties of AChE inhibitors in AD,18,19 cholinergic
drugs have shown little eﬃcacy to prevent the progression of
the disease. Consequently, there is no eﬃcient therapy to cure,
stop, or even slow the progression of the disease; therefore,
eﬀective therapeutics are urgently sought and needed.
The failure to ﬁnd such a drug or treatment is possibly due to
the multifactorial nature of AD. Thus, a single drug that acts on
a speciﬁc target to produce the desired clinical eﬀects might not
be suitable for the complex nature of AD. Accondingly, the
multitarget-directed ligand (MTDL) approach20−22 has been
the subject of increasing attention by many research groups,
which have developed a variety of compounds acting on very
diverse targets.23−26
We have previously reported N-((5-(benzyloxy)-1H-indol-2-
yl)methyl)prop-2-yn-1-amine (I, PF9601N)27 (Figure 1) as a
potent and selective propargylamine-containing MAO-B
inhibitor (MAOBI) possessing neuroprotective properties
that, unlike L-deprenyl does not generate amphetamines when
metabolized and possesses antiapoptotic properties.28 Next we
used I as hit compound with therapeutic potential for the
treatment of neurodegenerative diseases and started a project
targeted to ﬁnding an improved lead compound.
As a result of this eﬀort, we found that N-((5-(3-(1-
benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)-
methyl)-N-methylprop-2-yn-1-amine (II, ASS234, Figure 1) is
a multipotent drug able to inhibit human AChE (hAChE) and
human butyrylcholinesterase (hBuChE), showing inhibition of
human MAO-A and human MAO-B (hMAO-A, hMAO-B).29
The kinetic analysis demonstrated that compound II is not only
a reversible inhibitor of both hAChE and hBuChE with
micromolar aﬃnity but a highly potent irreversible inhibitor of
hMAO-A, similarly to clorgyline.30 The crystal structure of
human MAO-B in complex with compound II highlighted the
covalent adduct formed with the ﬂavin N5 atom, which, based
on the spectral changes, occurs also with the MAO-A
cofactor.30 Hybrid II inhibited Aβ1−42 self-aggregation more
eﬃciently than that of Aβ1−40, limiting the formation of ﬁbrillar
and oligomeric species,31 and completely blocked the
aggregation mediated by AChE of both Aβ1−42 and Aβ1−40.
Interestingly, compound II signiﬁcantly reduced Aβ1−42-
mediated toxicity in SH-SY5Y human neuroblastoma cells
and showed a signiﬁcant ability to capture free-radical species in
vitro as well as a potent eﬀect in preventing the Aβ1−42 induced
depletion of catalase and SOD-1.31,32 Finally, compound II is
able to cross the blood−brain barrier in vivo.33 Overall, these
data indicate that hybrid II is the desired lead compound in our
search for neurodegenerative diseases therapy.
On the basis of these results, we started a lead compound
optimization program, whose results are described now in this
manuscript. From this study, N-methyl-N-((1-methyl-5-(3-(1-
(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)-
methyl)prop-2-yn-1-amine (2, MBA236) has emerged as a
permeable, potent, irreversible, and quite selective hMAO-A
inhibitor (MAOAI) in the nanomolar range, showing also
moderate and almost equipotent hAChE vs hBuChE inhibition
power.
■ RESULTS AND DISCUSSION
Design. In Figure 1, we show the modiﬁcations in
compounds I and II which have resulted into the new 19
molecules that we have synthesized. Our selection was based on
QSAR analysis (see below) and simple functional changes on
compounds II (Figure 2) and I (Figure 3).
As depicted, the N-benzyl motif in compound II has been
eliminated (1) or modiﬁed incorporating diﬀerent substituents
in the phenyl ring, such as o-MeC6H5CH2 (2), p-CNC6H5CH2
(3), and N-[(8-O-methyl- or 8-O-(N,N′-dimethylcarbamoyl)]5-
methylen]quinolone (4 and 5) (Figure 2). Taking into account
the structure, inhibition power, and selectivity of compound I
for MAO B,27 the N(1)Me in compound II has been replaced
by a N1(H) leading to 6; the N(1)Me and (indole)C(2)-
CH2N(Me)CH2CCH in hybrid II has been replaced by a
N1(H) and (indole)C(2)CH2N(H)CH2CCH in 7 (Figure
2); compound 8 is like 7 (Figure 2), but the acetylene has been
substituted by a vinyl group. Compounds 9 and 10 (Figure 2)
are the N-benzyl- and N-phenyl-1,2,3-triazole derivatives,34
respectively, of compound II. Similarly, compounds 11 and 12
(Figure 2) result from hybrid II by eliminating the C(2)-
CH2N(Me)CH2CCH side chain by CH2OH, and CO2Et,35
respectively, and in both cases we have replaced the N(1)Me
group by N(1)H.
Regarding compound I,27 related transformations have
aﬀorded compounds 13−16 (Figure 3). Compounds 17−19
(Figure 3) are ladostigil/rasagiline-like carbamates, where we
wanted to explore the known ability of compounds bearing this
functional motif to inhibit ChEs.36 Results from recent MAO/
ChE literature, such as the substitution of an acetylene by a
triazole34 or the use of a multifunctional chelator derived from
8-hydroxyquinoline,37 have been used to design molecules 5, 9,
10, 14, and 15 (Figures 2 and 3).
QSAR Analysis. The 3D-QSAR study has been carried out
with main aim to explain and predict the binding on the active
sites of human MAO-A, MAO-B, AChE, and BuChE enzymes
based on the pharmacological activities27,31,35 previously
observed for the lead-improving program work with multi-
potent compound II (Supporting Information), and the results
are shown in Table 1.
Figure 1. Schematic structural and functional modiﬁcations in
compounds I and II leading to the new target molecules 1−19.
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In the data set of previously characterized indole
derivatives,27,31,35 the MAO-A pIC50 activity interval spanned
4 log units (3.07−9.10); for pIC50 (MAO-B), it was 5.6 log
units (4.00−10.60), for pIC50 (AChE) 4.2 log units (4.00−
8.17), and pIC50 (BuChE) 3.4 log units (4.00−7.44). The
relatively wide pIC50 interval of the training set provide broad
applicability domain for the 3D-QSAR models created. The
3D-QSAR (MAO A) model with two signiﬁcant components
(A = 2): R2, 0.94; leave-one-out cross validation Q2, 0.66;
training set parameters (R2Observed vs Predicted, 0.908; and RMSEE,
0.433), and test set parameters (R2Observed vs Predicted, 0.809; and
RMSEP, 0.617), was developed. The 3D-QSAR (MAO B)
model with two signiﬁcant components (A = 2): R2, 0.97;
leave-one-out cross validation Q2, 0.85; training set parameters
(R2Observed vs Predicted, 0.957; and RMSEE, 0.303), and Test set
parameters (R2Observed vs Predicted, 0.787; and RMSEP, 0.598) was
formed. Similarly, the 3D-QSAR (AChE) model with three
signiﬁcant components (A = 3): R2, 0.87; leave-one-out cross
validation Q2, 0.61, training set parameters (R2Observed vs Predicted,
0.873; and RMSEE, 0.431), and test set parameters
(R2Observed vs Predicted, 0.539; and RMSEP, 0.661) was developed.
The 3D-QSAR (BuChE) model with two signiﬁcant
components (A = 2): R2, 0.92; leave-one-out cross validation
Q2, 0.72; training set parameters (R2Observed vs Predicted, 0.922; and
RMSEE, 0.261), and test set parameters (R2Observed vs Predicted,
0.657; and RMSEP, 0.521) was created.35
The statistical parameters indicated that the 3D-QSAR
(MAO-A, MAO-B, AChE, BuChE) models could be used for
prediction of MAO-A, MAO-B, AChE, and BuChE inhibiting
activities for novel analogues of compounds I and II. Reliability
of the activities predictions is strongly related to the type and
extent of structural changes of the lead compounds.
3D-pharmacophores are derived from 3D maps of interaction
energies between the examined molecule and four chemical
probes: DRY (which represent hydrophobic interactions), O
(sp2 carbonyl oxygen, representing H-bond acceptor), N1
(neutral ﬂat NH, like in amide, H-bond donor), and the TIP
probe (molecular shape descriptor). The 3D pharmacophores
for MAO-A and MAO-B inhibiting activities of compound II
contain crucial favorable O-TIP/O−DRY/TIP-TIP/DRY-TIP
interactions to the propargylamine moiety and to the benzyl
group. Therefore, substitution of the benzyl moiety of hybrid II
with small groups, such as an o-Me in 2 (Figure 2), could
enhance the MAO-A and MAO-B inhibiting activity of the
examined compounds by facilitating the TIP-TIP/DRY-TIP
favorable interactions. The 3D-QSAR study conﬁrmed also
previous experimental ﬁndings that the propargylamine moiety
provides an essential positive inﬂuence on the MAO-A and
MAO-B inhibiting activity.35,38,39
Figure 2. Compounds 1−12 synthesized and designed from
compound II.
Figure 3. Synthesized compounds 13−19 designed from compound I.
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The 3D-pharmacophores for BuChE inhibiting activities of
lead compound II contain speciﬁc unfavorable TIP-TIP/DRY-
TIP interactions between the indole and the para position of
the benzyl moieties. Therefore, substitution with bulky
substituent at para position of the benzyl moiety, such as a
cyano group in 3 (Figure 2), could decrease BuChE inhibiting
activity of compound II derivatives (Table 1). The 3D-
pharmacophores for AChE inhibiting activities of compound II
contain a crucial favorable O−O interaction to the piperidine
ring and to ortho positions of the benzyl group. Thus, a small
substituent at ortho position of the benzyl ring, such as the
methyl group in compound 2 (Figure 2), could enhance AChE
inhibiting activity of lead compound II (Table 1).
In addition to 2, compounds 4, 3, 13, and 14 have also been
investigated by QSAR analysis, and their predicted IC50 values
are also shown in Table 1. The predicted IC50 values clearly
suggest that (a) compound II-donepezil type hybrids 2, 4, and
5, in this order, should be the most potent MAO-AI;, (b) the
compound I-like derivative 14 should be a more potent
inhibitor of MAO-A, AChE, and BuChE than 13, and (c) 2
should be the most potent inhibitor against all four enzymes.
Next, the designed compound II analogues were synthesized
and examined for MAO/ChE inhibitory activity.
Chemistry. The synthesis of the new molecules (Figures 2
and 3) has been achieved by standard or reported methods, in
very eﬃcient and short synthetic sequences, in good overall
yields (see Supporting Information). All new molecules gave
satisfactory analytical and spectroscopic data, in good agree-
ment with their structures.
Biological Evaluation. The biological evaluation, compris-
ing the hMAO-A/hMAO-B and hAChE/hBuChE inhibition,
has been carried out according to the protocols described in the
Supporting Information, following the usual methods.40,41 In
Table 1S (Supporting Information), we have shown the IC50
values for the inhibition of the MAOs and ChEs with all the 19
new compounds, using compounds I and II, reanalyzed in this
work42 as reference compounds. The established MAOI,
clorgyline and L-deprenyl, and the ChEI, donepezil, are also
reported for comparative purposes. Note that only seven
compounds, 2, 5−8, 11, and 12, were active simultaneously in
the four enzymes (Table 2). As shown in Supporting
Information, Table 1S, compound 6 is a moderate hMAO-AI
and hBuChEI, in the high micromolar range, but shows very
modest hMAO-B and hAChE inhibition power. 12 is almost
equipotent with 6 for the hMAO-A and hAChE inhibition, but
2.6-fold more, and 4.4-fold less potent than 6, for the inhibition
of hMAO-B and hBuChE, respectively. 7 is a poor hMAO-AI
and hMAO-BI, but a moderate hAChEI and BuChEI, in the
micromolar range. 8 is a quite poor hMAO-AI, hMAO-BI, and
hBuChEI but a modest hAChEI. Furthermore, 5 and 11 were
nonselective, potent hMAOI in the low micromolar range, but
moderate and equipotent ChE inhibitors.
However, among all these products, as predicted by the
QSAR analysis (see above), compound 2 (Table 2) was the
most potent hMAO-A, hMAO-B AChE, and BuChE multi-
potent inhibitor found in this work. Compound 2 is a very
potent, in the nanomoloar range, and selective hMAO-AI (Ki =
7.5 ± 0.9 nM), showing a potent and slightly selective hAChE
inhibition proﬁle (Ki = 1.3 ± 0.5 μM), in the micromolar range.
Compared with the reference compound II (Figure 4), the new
compound 2 is 9.2-fold and 6.5-fold more potent hMAO-AI
and hMAO-BI, respectively, 1.2-fold more potent hAChEI, and
only 1.5-fold less potent hBuChEI. Comparing with compound
I and the standard MAOIs, for the inhibition of MAO-A,
compound 2 is 45-fold more potent than compound I, 1.3-fold
less than clorgyline, and 10095-fold more potent than L-
deprenyl. Conversely, for the inhibition of MAO-B, compound
2 is 45-fold less, 358-fold more, and 10-fold less potent than
compound I, clorgyline, and L-deprenyl, respectively.
To sum up, compound 2 is a multipotent molecule of MAO
and ChE, showing a very attractive pharmacological proﬁle, as a
selective and very potent MAO-AI, with high MAO-B and
Table 1. Experimental and QSAR-Predicted Activities of
Novel MAO/ChE Inhibitors
compd experimental IC50 (hMAO-A)
a (nM) predicted IC50 (MAO-A)
2 6.3 ± 0.4 3.9 nM
4 10.3 ± 0.8 218.8 nM
5 257.6 ± 11.4 306.2 nM
14 310.6 ± 17.1 3.2 μM
13 630.1 ± 16.1 23.7 μM
compd experimental IC50 (hMAO-B)
a (nM) predicted IC50 (MAO-B)
2 183.6 ± 7.4 100.7 nM
13 164.7 ± 12.1 662.2 nM
5 196.3 ± 7.8 38.8 μM
14 273.1 ± 8.9 58.5 μM
4 7.9 ± 0.5 73.1 μM
compd experimental IC50 (hAChE) (μM) predicted IC50 (AChE)
2 2.8 ± 0.1 849.2 nM
5 8.4 ± 0.9 3.0 μM
14 b 4.0 μM
4 c 10.3 μM
13 b 11.1 μM
compd experimental IC50 (hBuChE) (μM) predicted IC50 (BuChE) (μM)
2 4.9 ± 0.2 1.3
5 5.9 ± 0.4 4.4
4 b 9.8
14 b 14.8
13 b 202.8
aAfter 15 min preincubation, so not directly comparable with the
predicted IC50 values.
bInactive at 100 μM (highest concentration
tested). c100 μM inhibits the corresponding MAO activity by
approximately 40−50%. At higher concentration the compounds
precipitate.
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potent hAChE/hBuChE inhibition power. It must be also
concluded that all our present and past eﬀorts29 to transform
compound I into a multipotent MAO/ChE compound, by
transforming the benzyl group into the ChE donepezil-like
pharmacophore, have met with success but at the cost of
loosing signiﬁcant MAO-B inhibition capacity.
Taking into account these ﬁndings, we have performed
further studies on the inhibition mechanism of action of
compound 2.
Figures 5 and 6 show the results of the reversibility test43 on
hMAO. Compound 2 binds as an irreversible inhibitor on both
enzyme isoforms, maintaining near a 90% inhibition after the
dilution of the preincubated mixture. The IC50 decreased from
14.6 ± 1.2 nM in reversible conditions (no preincubation and
substrate concentration 2 × Km) to 6.3 ± 0.4 nM assayed with
saturating substrate after a 15 min incubation.
Nevertheless, the recovery of ChE activity after compound 2
on ChEs was signiﬁcantly greater (around 20%), allowing us to
Table 2. IC50 Values for the Inhibitory Eﬀects of Test Compounds on the Enzymatic Activity for Human MAO or ChE Isoforms
and Selectivity Ratios for MAO-B [IC50 (MAO-A)]/[IC50 (MAO-B)] or for AChE ([IC50 (AChE)]/[IC50 (BuChE)]
a
compd hMAO-A hMAO-B ratio hAChE (μM) hBuChE (μM) ratio
2 6.3 ± 0.4 nMb 183.6 ± 7.4 nM 0.03 2.8 ± 0.1 4.9 ± 0.2 0.57
5 257.6 ± 11.4 nMc 196.3 ± 7.8 nM 1.3 8.4 ± 0.9 5.9 ± 0.4 1.4
6 9.1 ± 0.7 μMc 35.1 ± 2.8 μM 0.26 15.4 ± 0.9 7.1 ± 0.5 2.2
7 19.2 ± 1.3 μMc 33.6 ± 1.5 μM 0.57 4.9 ± 0.3 7.3 ± 0.8 0.67
8 45.3 ± 1.6 μMc 21.3 ± 1.9 μM 2.1 4.6 ± 0.3 40.6 ± 2.2 0.11
11 876.6 ± 25.2 nM 1.0 ± 0.02 μM 0.87 9.6 ± 0.08 9.7 ± 0.7 0.99
12 9.1 ± 0.3 μM 13.5 ± 1.1 μM 0.67 13.6 ± 1.4 31.2 ± 3.1 0.43
II 58.2 ± 1.2 nMb 1.2 ± 0.1 μM 0.05 3.4 ± 0.2 3.3 ± 0.2 1.03
I 287.3 ± 11.2 nMb 4.1 ± 0.7 nM 70 e e
clorgyline 4.7 ± 0.2 nMb 65.8 ± 1.6 μM 0.000071 e e
L-deprenyl 63.6 ± 1.3 μMb 18.2 ± 0.9 nM 3494 e e
donepezild nd nd 0.016 ± 0.001 8.2 ± 0.2
aAll IC50 values shown in this table are the mean ± SD from ﬁve experiments. hMAO: IC50 values were determined after 15 min preincubation of
inhibitor with the enzyme. hChE: IC50 values were determined after 10 min preincubation of inhibitor with the enzyme. Level of statistical
signiﬁcance: bP < 0.01 or cP < 0.05 versus the corresponding IC50 values obtained against MAO-B, as determined by ANOVA/Dunnett’s.
dReference
23. eInactive at 100 μM (highest concentration tested). nd = not determined.
Figure 4. Structure of compound 2 and its IC50 values for the
inhibition of MAO and ChEs compared with the reference compound
II.
Figure 5. Recovery of hMAO-A activity after dilution following
incubation (30 min at room temperature) of the 100× enzyme
concentration with 10-fold IC50 concentration of compound 2 or
clorgyline. The control was carried out by preincubating in the absence
of inhibitor and diluting in the same way. Results are expressed as
percentage of control. Represented data are mean ± SD of ﬁve
independent assays.
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classify it as a slow inhibitor (Figure 7). Kinetic assays
performed with this compound have shown ambiguous results,
probably due to the low degree of reversibility of inhibition
achieved on hAChE and hBuChE. As a result of the low
reversibility, the pattern of the Lineweaver−Burk representa-
tion appears to indicate a mixed model for both enzymes
(results not shown).
With the aim of investigating compound 2 recognition with
respect to either MAO-A, MAO-B, AChE, and BuChE
enzymes, molecular modeling studies have been carried out.
The theoretical investigation has been focused on the ligand−
enzyme interaction and target structural perturbation produced
by compound 2 comparing these information with respect to
the same data coming from the related compound II
(Supporting Information). Only one proposed structure was
found for compound 2 in hMAO-A and two for hMAO-B, with
a global miminum population equal to 96.11%. Compounds II
and 2 both adopted bent conformations in hMAO-A but were
linear in hMAO−B (Figure S1, Supporting Information).
Overall, the interactions between compounds II, 2, and the
MAOs are driven by both steric hindrance and hydrophobic
contribution with an additional electrostatic term present in
hMAO-A. Using the target RMSd matrix, each MD trajectory
was clustered into nine groups. The visual inspection of the 10
structures for each inhibitor with each enzyme clearly indicates
the conformation stabilizing eﬀect of the o-methyl group in
hybrid 2 (Figure S4, Supporting Information).
In this work, we have designed a new and multipotent
MAOI. MAOI are well-known for showing diverse therapeutic
potential as the result of combining selectivity and (ir)reversible
modes of binding.15 MAO-AI have been used mostly in the
treatment of depression and anxiety,44 and MAO-BI for the
treatment of PD.45 Recent studies have shown that MAO-A is
involved in the regulation of serotonin for ventricular
remodeling via activation of the serotonin2A receptors.46 In
the aged heart, the increased MAO-A concentrations results in
high levels of oxygen peroxide, leading to severe cardiomyocyte
damage.47 A survey of the current literature on MAOIs shows
also that one of the major reasons for designing new and
speciﬁc inhibitors is to function as cardioprotectants for the
age-dependent increase of MAO A in the heart.48 Although
MAO-AIs enhance extracellular levels of dopamine produced
from L-dopa, irreversible and selective MAO-AI cannot be used
in the PD therapy because of cardiovascular side eﬀects.49
Another disadvantage of an irreversible MAO-AI is the
hypertensive “cheese eﬀect”50 due to the predominance of
MAO-A in the gut wall to metabolize tyramine in fermented
foods such as cheese and beer. Hypertensive crises may be
prevented by using reversible rather than irreversible MAO-AI
or tissue-speciﬁc inhibitors such as the brain-selective
ladostigil.51
The cases of ladostigil52 and M30D53 (Figure 8) are of
interest for this project and future possible endeavors because
both are ChE, MAO-A, and MAO-B irreversible inhibitors with
potential therapeutic applications as antidepressants, antipar-
kinson, and anti-Alzheimer drugs.44 Ladostigil51 (Figure 8) was
designed from rasagiline, a MAO-BI, bearing a propargylamine
motif, responsible for the neuroprotective properties, and a
carbamate group, aﬀording ChE inhibitory activity. M30D53
(Figure 8) shows an inhibitory proﬁle against ChE (hAChE
IC50 = 0.52 ± 0.07 μM; hBuChE IC50 = 44.90 ± 6.10 μM) and
against MAO (ratMAO-A, IC50 = 0.0077 ± 0.0007 μM;
ratMAO-B, IC50 = 7.90 ± 1.34 μM) very similar to the one
observed for 2 (Table 2), as well as other properties as
potential drugs for treating AD.
In Vitro Blood−Brain Barrier Permeation Assay.
Finally, to evaluate the brain penetration, we used the
PAMPA−BBB method described by Di,54 and subsequently
optimized by Rodriǵuez-Franco et al. for molecules with limited
water-solubility.55−57
The in vitro permeability (Pe) value of compound 2 through
a lipid extract of porcine brain was determined by using
PBS:ethanol (70:30). In the same assay, 11 commercial drugs
of known CNS penetration were also tested and their
experimental values were compared to reported values, giving
a good lineal correlation, Pe (exp) = 1.4442 Pe (bibl) + 6.5263
(R2 = 0.95). From this equation and taking account the limits
established by Di for BBB permeation,54 we found that
Figure 6. Recovery of hMAO-B activity after dilution following
incubation (30 min at room temperature) of the 100× enzyme
concentration with 10-fold IC50 concentration of compound 2 or L-
deprenyl. The control was carried out by preincubating in the absence
of inhibitor and diluting in the same way. Results are expressed as
percentage of control. Represented data are mean ± SD of ﬁve
independent assays.
Figure 7. Recovery of hAChE (gray column) and hBuChE (black
column) activity after the dilution of the incubation (30 min at room
temperature) of the 100× enzyme concentration and 10-fold IC50 of
compound 2. The control was carried out by preincubating in the
absence of inhibitor and diluting in the same way. Results are
expressed as percentage of control. Represented data are mean ± SD
of ﬁve independent assays. Figure 8. Structures of ladostigil and M30D.
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compounds with permeability values above 12.3 × 10−6 cm s−1
could penetrate into the CNS. Derivative 2 showed Pe = 14.4 ±
0.4 × 10−6 cm s−1, and thus, it could cross BBB by passive
diﬀusion (Supporting Information).
■ CONCLUSIONS
In this paper, we have reported the design, synthesis, and
biological evaluation of 19 new donepezil−indolyl hybrids as
multifunctional drugs able to bind MAO and ChE enzymes,
using the MAO B inhibitor I hit and the multipotent II hybrid
lead as references for lead-optimization in order to discover a
new lead compound for deeper in vivo preclinical investigations
targeted to neurological disorders. The QSAR-designed
compound II analogues have been synthesized and examined
for MAO/ChE inhibitory activity. As shown in Figure 4, the
potent MAO/ChE inhibiting activity for the novel ligand 2
conﬁrmed the quality of the optimized 3D-pharmacophores for
use in future work to design novel donepezil−indolyl hybrids.
We have found signiﬁcant biological activity on the four
enzymes studied in almost half of the synthesized structures.
The most promising compound of the series, 2, acted as an
irreversible hMAO-AI, potent in the nanomolar range, nine
times more potent than the reference compound II, and 29-fold
more selective for hMAO-A over hMAO-B. Inhibition of the
ChEs by hybrid 2 is in the micromolar range, slightly better
than compound II for hAChEs although slightly poorer for
hBuChE. Although we are confronted with unbalanced, highly
preferred MAO vs ChE inhibition, the potency and desired
balance between targets in MTDL-based strategies is not
known.58 Molecular modeling studies59 reported similar
binding modes of compounds II and 2 in all the evaluated
biological targets. The o-Me group in compound 2 improves
the ligand recognition, increasing the ligand−enzyme hydro-
phobic interaction in hBuChE and π−π stacking in hMAO-A,
hMAO-B, and hAChE. Thus, it is clear that simple modiﬁcation
of compound II, such as the incorporation of an o-methyl
instead of a hydrogen in the phenyl ring of the N-
benzylpiperidine motif, produces signiﬁcant qualitative and
quantitative pharmacological changes in the inhibition of MAO
and ChE enzymes. Finally, the ADMET virtual analysis59
suggests that inhibitor 2 should present good drug-like
characteristics similar to compound II, with a slightly better
brain penetration ability, a prediction experimentally conﬁrmed
by the in vitro blood−brain barrier permeation assay.
Consequently, we have fulﬁlled our initial expectations, that a
new, easily available, permeable multipotent MAO inhibitor has
been discovered. The related pharmacological properties with
ladostigil, clearly support projected in vivo studies for proof of
concept targeted to probe the suitability of compounds 2 and II
to treat neurodegeneratives disorders such AD or PD.
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(41) Yañ́ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis-
and trans-resveratrol on noradrenaline and 5-hydroxytryptamine
uptake and on monoamine oxidase activity. Biochem. Biophys. Res.
Commun. 2006, 344, 688−695.
(42) Reevaluation of reference inhibitors has been carried out under
diﬀerent conditions (enzymatic source and concentrations, measure-
ment method) than our previous study (refs 29 and 30, cited herein)
but ﬁnding similar qualitative inhibition and selectivity for all
compounds tested. Because IC50 values depends directly on enzyme
and substrate concentrations, normal quantitative discrepancies were
achieved.
(43) Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug
Discovery; Wiley-Interscience: Hoboken, NJ, 2005.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm501501a | J. Med. Chem. 2014, 57, 10455−1046310462
(44) Youdim, B. H. M.; Edmondson, D.; Tipton, K. F. The
therapeutic potential of monoamine oxidase inhibitors. Nature Rev.
Neurosci. 2006, 7, 295−309.
(45) Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-
Ikola, O.; Palm, R. Selegiline slows the progression of the symptoms of
Parkinson disease. Neurology 2006, 66, 1200−1206.
(46) Lairez, O.; Calise, D.; Bianchi, P.; Ordener, C.; Spreux-
Varoquaux, O.; Guilbeau-Frugier, C.; Escourrou, G.; Seif, I.; Roncalli,
J.; Pizzinat, N.; Galinier, M.; Parini, A.; Mialet-Peŕez, J. Genetic
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Hernańdez-Ledesma, B.; Bartolome,́ B. Novel tacrine−melatonin
hybrids as dual-acting drugs for Alzheimer disease, with improved
acetylcholinesterase inhibitory and antioxidant properties. J. Med.
Chem. 2006, 49, 459−462.
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